Advertisement
Research Article| Volume 192, P109-115, April 01, 2023

Download started.

Ok

Safety and Feasibility of Staged Versus Concomitant Transcatheter Edge-to-Edge Mitral Valve Repair After Transcatheter Aortic Valve Implantation

Published:February 14, 2023DOI:https://doi.org/10.1016/j.amjcard.2023.01.037
      The data on the safety and feasibility of performing concomitant or staged transcatheter edge-to-edge repair (TEER) of the mitral valve with transcatheter aortic valve implantation (TAVI) remains limited. The Nationwide Readmission Database was used to identify TEER and TAVI procedures from October 1, 2015 to December 31, 2019, using the International Classification of Diseases, Tenth Revision, Clinical Modification administrative data. A total of 627 weighted cases of TEER and TAVI procedures were included in the analysis. Of those cases, 453 underwent staged TEER after TAVI, whereas 174 had concomitant TAVI and TEER during the same admission. Patients who underwent staged procedures were mostly men (64.8%, p = 0.02) and had a higher median age of 85 years (interquartile range 79 to 88) versus 82 years (interquartile range 72 to 86) in the concomitant procedure group. The adjusted propensity-matched mortality rate was similar for staged versus same-admission procedures (6.1% vs 7.0%, p = 0.79). In-hospital complication rates, including acute kidney injury, vascular complications, need for percutaneous coronary intervention, mechanical support, and pacemaker implantation, were higher for the same-admission TEER and TAVI group than TEER performed as a staged procedure. Nonhome facility discharges and length of hospital stay (15 vs 4 days) were also significantly higher for the concomitant same-admission TEER and TAVI groups. In conclusion, there was no difference in in-hospital mortality rate between patients who underwent concomitant or staged TEER and TAVI procedures, whereas complication rates were significantly higher in the concomitant group.

      Graphical Abstract

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Otto CM
        • Nishimura RA
        • Bonow RO
        • Carabello BA
        • Erwin JP
        • Gentile F
        • Jneid H
        • Krieger EV v.
        • Mack M
        • McLeod C
        • O'gara PT
        • Rigolin VH
        • Sundt TM
        • Thompson A
        • Toly C.
        2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines.
        Circulation. 2021; 143: e35-e71
        • Feldman T
        • Kar S
        • Rinaldi M
        • Fail P
        • Hermiller J
        • Smalling R
        • Whitlow PL
        • Gray W
        • Low R
        • Herrmann HC
        • Lim S
        • Foster E
        • Glower D
        • EVEREST Investigators
        Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.
        J Am Coll Cardiol. 2009; 54: 686-694
        • Glower D
        • Ailawadi G
        • Argenziano M
        • Mack M
        • Trento A
        • Wang A
        • Lim DS
        • Gray W
        • Grayburn P
        • Dent J
        • Gillam L
        • Sethuraman B
        • Feldman T
        • Foster E
        • Mauri L
        • Kron I
        • EVEREST II Investigators
        EVEREST II randomized clinical trial: predictors of mitral valve replacement in de novo surgery or after the MitraClip procedure.
        J Thorac Cardiovasc Surg. 2012; 143: S60-S63
        • Tirado-Conte G
        • McInerney A
        • Jimenez-Quevedo P
        • Carnero M
        • Marroquin Donday LA
        • Agustin A de
        • Witberg G
        • Pozo E
        • Islas F
        • Marcos-Alberca P
        • Cobiella J
        • Koronowski R
        • Macaya C
        • Rodes-Cabau J
        • Nombela-Franco L
        Managing the patient undergoing transcatheter aortic valve replacement with ongoing mitral regurgitation.
        Expert Rev Cardiovasc Ther. 2021; 19: 711-723
        • Feldt K
        • Palma R de
        • Bjursten H
        • Petursson P
        • Nielsen NE
        • Kellerth T
        • Jönsson A
        • Nilsson J
        • Rück A
        • Settergren M
        Change in mitral regurgitation severity impacts survival after transcatheter aortic valve replacement.
        Int J Cardiol. 2019; 294: 32-36
        • Bedogni F
        • Latib A
        • Marco F de
        • Agnifili M
        • Oreglia J
        • Pizzocri S
        • Latini RA
        • Lanotte S
        • Petronio AS
        • Carlo M de
        • Ettori F
        • Fiorina C
        • Poli A
        • Cirri S
        • Servi S de
        • Ramondo A
        • Tarantini G
        • Marzocchi A
        • Fiorilli R
        • Klugmann S
        • Ussia GP
        • Tamburino C
        • Maisano F
        • Brambilla N
        • Colombo A
        • Testa L
        Interplay between mitral regurgitation and transcatheter aortic valve replacement with the CoreValve Revalving System: a multicenter registry.
        Circulation. 2013; 128: 2145-2153
        • Cortés C
        • Amat-Santos IJ
        • Nombela-Franco L
        • Muñoz-Garcia AJ
        • Gutiérrez-Ibanes E
        • La Torre Hernandez JM de
        • Córdoba-Soriano JG
        • Jimenez-Quevedo P
        • Hernández-García JM
        • Gonzalez-Mansilla A
        • Ruano J
        • Jimenez-Mazuecos J
        • Castrodeza J
        • Tobar J
        • Islas F
        • Revilla A
        • Puri R
        • Puerto A
        • Gómez I
        • Rodés-Cabau J
        • San Román JA
        Mitral regurgitation after transcatheter aortic valve replacement: prognosis, imaging predictors, and potential management.
        JACC Cardiovasc Interv. 2016; 9: 1603-1614
        • Connelly KA
        • Creati L
        • Lyon W
        • Yii M
        • Rosalion A
        • Wilson AC
        • Santamaria J
        • Jelinek VM.
        Early and late results of combined mitral-aortic valve surgery.
        Heart Lung Circ. 2007; 16: 410-415
        • Val D del
        • Regueiro A
        • Rodríguez-Gabella T
        • Paradis JM
        • Puri R
        • Rodés-Cabau J
        Concomitant or Staged transcatheter Treatment for Severe Combined Aortic and Mitral Valve Disease.
        Rev Esp Cardiol (Engl Ed). 2018; 71: 676-679
        • Sürder D
        • Altwegg L
        • Hürlimann D
        • Felix C
        • Grünenfelder J
        • Corti R.
        Percutaneous double valve intervention.
        Eur Heart J. 2011; 32: 636
        • Kische S
        • D'Ancona G
        • Paranskaya L
        • Schubert J
        • Arsoy N
        • Hauenstein KH
        • Alozie A
        • Jovanovich B
        • Nienaber C
        • Ince H
        Staged total percutaneous treatment of aortic valve pathology and mitral regurgitation: institutional experience.
        Catheter Cardiovasc Interv. 2013; 82: E552-E563
      1. Healthcare Cost and Utilization Project (HCUP). Overview of the nationwide readmissions database (NRD). Available at: https://www.hcup-us.ahrq.gov/nrdoverview.jsp. Accessed on 8 February 2023.

        • Ho DE
        • Imai K
        • King G
        • Stuart EA.
        MatchIt: nonparametric preprocessing for parametric causal inference.
        J Stat Softw. 2011; 42: 1-28
        • Muratori M
        • Fusini L
        • Tamborini G
        • Ghulam Ali S
        • Gripari P
        • Fabbiocchi F
        • Salvi L
        • Trabattoni P
        • Roberto M
        • Agrifoglio M
        • Alamanni F
        • Bartorelli AL
        • Pepi M
        Mitral valve regurgitation in patients undergoing TAVI: impact of severity and etiology on clinical outcome.
        Int J Cardiol. 2020; 299: 228-234
        • Chakravarty T
        • Belle E van
        • Jilaihawi H
        • Noheria A
        • Testa L
        • Bedogni F
        • Rück A
        • Barbanti M
        • Toggweiler S
        • Thomas M
        • Khawaja MZ
        • Hutter A
        • Abramowitz Y
        • Siegel RJ
        • Cheng W
        • Webb J
        • Leon MB
        • Makkar RR
        Meta-analysis of the impact of mitral regurgitation on outcomes after transcatheter aortic valve implantation.
        Am J Cardiol. 2015; 115: 942-949
        • Elbadawi A
        • Elgendy IY
        • Afify H
        • Eid M
        • Hamed M
        • Abowali HA
        • Kleiman NS
        • Reardon MJ
        • Kapadia SR
        • Goel SS.
        Combined transcatheter Aortic and Mitral Valve Interventions: insights from a National Database.
        JACC Cardiovasc Interv. 2021; 14: 1505-1507
        • Witberg G
        • Codner P
        • Landes U
        • Barbanti M
        • Valvo R
        • de Backer O
        • Ooms JF
        • Sievert K
        • Sabbagh A el
        • Jimenez-Quevedo P
        • Brennan PF
        • Sedaghat A
        • Masiero G
        • Werner P
        • Overtchouk P
        • Watanabe Y
        • Montorfano M
        • Bijjam VR
        • Hein M
        • Fiorina C
        • Arzamendi D
        • Rodriguez-Gabella T
        • Fernández-Vázquez F
        • Baz JA
        • Laperche C
        • Grasso C
        • Branca L
        • Estévez-Loureiro R
        • Benito-González T
        • Amat Santos IJ
        • Ruile P
        • Mylotte D
        • Buzzatti N
        • Piazza N
        • Andreas M
        • Tarantini G
        • Sinning JM
        • Spence MS
        • Nombela-Franco L
        • Guerrero M
        • Sievert H
        • Sondergaard L
        • Mieghem NM van
        • Tchetche D
        • Webb JG
        • Kornowski R
        Transcatheter treatment of residual significant mitral regurgitation following TAVR: A multicenter registry.
        JACC Cardiovasc Interv. 2020; 13: 2782-2791
        • Figulla HR
        • Lauten A
        • Hamm C
        • Lange R
        • Sack S
        • Mohr FW
        TCT-715 Developing of a TAVR risk score for the prediction of mortality after transcatheter aortic valve replacement.
        J Am Coll Cardiol. 2014; 64 (B210–B210)
        • Alkhouli M
        • Palacios IF
        • Jneid H.
        Risk stratification of patients undergoing mitral TEER.
        J Am Coll Cardiol. 2022; 79: 574-576